Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms.

Abstract

Breast cancer is a common malignant tumor in women, with a highest incidence and mortality among all of the female malignant tumors. Notably, targeted therapy has achieved impressive success in the treatment of breast cancer. As one class of the anti-tumor targeted therapeutics, Cyclin-Dependent Kinases 4/6CDK4/6inhibitors have shown good clinical activity in treating breast cancer. Nevertheless, despite the promising clinical outcomes, intrinsic or acquired resistance to CDK4/6 inhibitors has limited the benefits of this novel target therapy. In the present review, we provide an overview of the currently known molecular mechanisms of resistance to CDK4/6 inhibitors, and discuss the potential strategies to overcoming drug resistance improving the outcomes for breast cancer patients treated with CDK4/6 inhibitors.

• Authors: Bin Wang, Rui Li, Shuai Wu, Xin Liu, Jianlin Ren, Jing Li, Kaixin Bi, Yanhong Wang, Hongyan Jia
• Journal: Frontiers in oncology (Front Oncol) Vol. 11 Pg. 651541 ( 2021) ISSN: 2234-943X [Print] Switzerland
• PMID: 34123801 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2021 Wang, Li, Wu, Liu, Ren, Li, Bi, Wang and Jia.